TLR9 and acute kidney injury: However, the endogenous mtDNA-mediated activation of TLR9 should contribute to the pathogenesis of AKI, and targeting TLR9 using siRNA or selective antagonist through targeting tubular delivery could protect against AKI (79, 81, 82).